| A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. | |
| | |
MedLine Citation:
|
PMID: 17031561 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM). OBJECTIVES: To determine 6-month progression-free survival (6PFS) and toxicity of temozolomide plus thalidomide in adults with recurrent GBM. PATIENTS AND METHODS: Eligible patients had recurrent GBM after surgery, radiotherapy, and/or adjuvant chemotherapy. Temozolomide was given at 150-200 mg/m(2)/day on days 1-5 of each 28-day cycle. Thalidomide was given orally at 400 mg at bedtime (days 1-28) and increased to 1,200 mg as tolerated. Patients were evaluated with magnetic resonance imaging scans every 56 days. The study was designed to detect an increase of the historical 6PFS for GBM from 10 to 30%. RESULTS: Forty-four patients were enrolled, 43 were evaluable for efficacy and safety. The study population included 15 women, 29 men; median age was 53 years (range 32-84); median Karnofsky performance status was 80% (range 60-100%). Thirty-six (82%) patients were chemotherapy-naïve. There were 57 reports of toxicity of grade 3 or greater. Non-fatal grade 3-4 granulocytopenia occurred in 15 patients (34%). The objective response rate was 7%. The estimated probability of being progression-free at 6 months with this therapy is 24% [95% confidence interval (C.I.) 12-38%]. The median time to progression is 15 weeks (95% C.I. 10-20 weeks). There was no observed correlation between serum levels of vascular endothelial growth factor, basic fibroblast growth factor, and IL-8 and the 6PFS outcome. CONCLUSION: This drug combination was reasonably safe, but with little indication of improvement compared to temozolomide alone. |
| | |
Authors:
|
Morris D Groves; Vinay K Puduvalli; Susan M Chang; Charles A Conrad; Mark R Gilbert; Ivo W Tremont-Lukats; Ta-Jen Liu; Pamela Peterson; David Schiff; Timothy F Cloughesy; Patrick Y Wen; Harry Greenberg; Lauren E Abrey; Lisa M DeAngelis; Kenneth R Hess; Kathleen R Lamborn; Michael D Prados; W K Alfred Yung |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural Date: 2006-09-22 |
Journal Detail:
|
Title: Journal of neuro-oncology Volume: 81 ISSN: 0167-594X ISO Abbreviation: J. Neurooncol. Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-01-22 Completed Date: 2007-04-05 Revised Date: 2007-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 8309335 Medline TA: J Neurooncol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 271-7 Citation Subset: IM |
Affiliation:
|
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA. mgroves@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Brain Neoplasms / drug therapy*, mortality Dacarbazine / analogs & derivatives, therapeutic use Disease-Free Survival Enzyme-Linked Immunosorbent Assay Female Glioblastoma / drug therapy*, mortality Humans Male Middle Aged Neoplasm Recurrence, Local / drug therapy* North America Survival Analysis Thalidomide / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
CA16672/CA/NCI NIH HHS; CA62399/CA/NCI NIH HHS; CA62412/CA/NCI NIH HHS; CA62422/CA/NCI NIH HHS; M01-RR00042/RR/NCRR NIH HHS; M01-RR00056/RR/NCRR NIH HHS; M01-RR00079/RR/NCRR NIH HHS; M01-RR0865/RR/NCRR NIH HHS; U01CA62405/CA/NCI NIH HHS; U01CA62407/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
4342-03-4/Dacarbazine; 50-35-1/Thalidomide; 85622-93-1/temozolomide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Resveratrol inhibits cell growth and induces apoptosis of rat C6 glioma cells.
Next Document: EGF genetic polymorphism is associated with clinical features but not malignant phenotype in neurofi...